West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 14, 2026

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

Zacks Investment Research • Aug 14, 2026

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

Zacks Investment Research • Aug 13, 2026

WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook

WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.

Zacks Investment Research • Aug 13, 2026

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

Zacks Investment Research • Aug 13, 2026

Top 50 High-Quality Dividend Growth Stocks For August 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. The universe delivered a 10.44% YTD return through July, closely matching SPY but trailing SCHD, with several individual stocks significantly outperforming. Currently, 40 stocks in the universe offer a forward return estimate of at least 10%, with 25 appearing potentially undervalued based on free cash flow analysis.

Seeking Alpha • Aug 9, 2026

Conestoga SMid Cap Composite Q2 2026 Portfolio Review

West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.

Seeking Alpha • Jul 31, 2026

Best Dividend Aristocrats For August 2026

NOBL is outperforming SPY YTD in 2026, returning 12.9% versus SPY's 7.88%, with 45 Aristocrats ahead of SPY. Dividend growth among Aristocrats in 2026 averages 4.10%, with recent increases from ALB, FAST, PPG, SJM, and SWK. 25 Dividend Aristocrats appear undervalued and offer estimated long-term annualized returns of at least 10% using dividend yield theory.

Seeking Alpha • Jul 29, 2026

West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.

Seeking Alpha • Jul 24, 2026

West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components

West Pharmaceutical Services raised its annual profit and revenue forecasts on Thursday as strong demand for components used ​in injectable drugs, including diabetes and obesity treatments, ‌helped it beat second-quarter estimates.

Reuters • Jul 23, 2026